Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.

ABSTRACT:

SUBMITTER: Gentile M 

PROVIDER: S-EPMC7494850 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature